Levetiracetam Solution
Product Images NDC 70752-203

This text pertains to a medication called Levetiracetam Oral Solution, USP, containing 100 mg of Levetiracetam USP per mL. The usual dosage information can be found in the package insert. It highlights essential storage instructions of storing the solution at 25°C with excursions permitted to 15-30°C. The medication should be dispensed in a tight, light-resistant container with a child-resistant closure. The manufacturer is Quagen Pharmaceuticals LLC, based in West Caldwell, NJ. It is essential to keep this medication and all others out of the reach of children. The text also includes a GTIN number for the product and mentions that the medication is made in the USA.*

This text provides information about calculating a patient's total daily dose based on their weight and a specific medication concentration. The formula suggests multiplying the dose in milligrams per kilogram per day by the patient's weight in kilograms to determine the daily dose. It then indicates that the total daily dose in milliliters can be calculated as 100 divided by the milligrams per milliliter concentration of the medication.*

This text provides formulas to calculate Creatinine clearance (CLer) for adults based on age, weight, and serum creatinine levels. The first formula involves subtracting age from 140 and then multiplying that by the weight in kilograms. The second formula is used to calculate CLer and involves multiplying 72 by the serum creatinine level in mg/dL, with a correction factor of 0.85 for female patients.*

The text provides information on the Responder Rate (>50% Reduction From Baseline) in Study 1. It includes percentages for different treatment groups: Placebo (N=95), Levetiracetam 1000 mg/day (N=97), and Levetiracetam 3000 mg/day (N=101). The data shows the percentage of responders in each group. Additionally, it mentions that one of the Levetiracetam groups had a statistically significant difference compared to the Placebo group.*

The provided text discusses the responder rate in Study 2, focusing on the percentage of patients who experienced more than a 50% reduction in symptoms from the baseline. The data compares the results between a placebo group and two different doses of Levetiracetam (1000 mg/day and 2000 mg/day). The analysis indicates that there was a statistically significant difference between the Levetiracetam groups and the placebo group.*

This text provides information on the percentages of responses in a study comparing Levetiracetam at 3000 mg/day versus a Placebo group (N=104 for Placebo, N=180 for Levetiracetam). It indicates that there is a statistically significant difference between the Levetiracetam group and the Placebo group.*

This text provides a comparison of responder rates for Levetiracetam (N=101) and Placebo (N=97) in a study. The responder rate for Levetiracetam is indicated at 44.6%, while for Placebo it is not specified but marked as statistically significant versus Placebo. The graph shows the breakdown of responder rates at different percentage levels for each group.*

This text provides information on the Responder Rate for all patients ages 1 month to <4 years showing a 50% reduction from baseline in Study 5. The responder rate with Levetiracetam is 43.1%, while with Placebo it is 19.6%. The data indicates that Levetiracetam has shown to be statistically significant versus Placebo.*

This data shows the Responder Rate (50% Reduction From Baseline) in Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency per week in Study 7. The chart displays the percentage of patients who experienced a 50% reduction in seizures. In this study, the group treated with Levetiracetam had a statistically significant improvement compared to the placebo group.*